Gland Pharma Share Price Gains Over 7% After Q1 FY27 Earnings Results: Total Income Up 19.1% YoY

On August 10, 2026, Gland Pharma Limited released its unaudited consolidated financial results for the quarter ended June 30, 2026, detailing the company's income and profit figures compared to previous periods, as per the exchange filings. 

Gland Pharma Q1 FY27 Earnings Results 

The total income for Gland Pharma reached ₹1,861.50 crore for the quarter ended June 30, 2026. This reflects a 19.1% increase on a year-over-year basis compared to the ₹1,563.15 crore recorded in the same period during the previous year.  

On a quarter over quarter basis, the total income experienced a rise of 0.4% from the ₹1,854.26 crore reported for the quarter ended March 31, 2026. 

The net profit for Gland Pharma stood at ₹316.96 crore for the quarter ended June 30, 2026. This figure marks a 47.1% increase year over year when compared to the ₹215.48 crore recorded in the corresponding quarter of the previous year.  

However, the profit experienced a decline of 13.6% on a quarter over quarter basis, down from the ₹366.68 crore reported for the quarter ended March 31, 2026. 

Annual Performance for FY26 

For the full financial year 2026, the company recorded a total income of ₹6,746.98 crore. During the same annual period, the net profit for Gland Pharma reached a total of ₹1,027.32 crore. 

Division Operations 

The core contract development and manufacturing organization (CDMO) vertical brought in ₹891.5 million. This critical business segment expanded by 20% year-on-year to constitute exactly half of total revenues. 

The business-to-business (B2B) supply vertical contributed the remaining half of revenue, generating ₹908.8 million. This division registered a stable 19% year-on-year top-line expansion. 

Geographic Markets 

The United States remained the largest commercial market, bringing in ₹981.0 million with 32% annual growth. Operations across European markets expanded by 20% year-on-year to generate ₹395.4 million. 

The domestic Indian market segment grew by 12% annually to register ₹66.6 million. The rest of the world combined contributed ₹303.9 million to the overall top-line performance. 

Strategy and Pipeline 

Quarterly research and development investments stood at ₹77.2 million, accounting for 4% of operational revenues. The corporation successfully rolled out four new drug molecules within the United States market. 

The enterprise secured seven new Abbreviated New Drug Application (ANDA) approvals from the US regulator. Their complete U.S. portfolio has reached a cumulative total of 342 approved filings. 

Read More: Titan Share Price Gains 2% After Q1FY27 Results: Net Profit Surges 63%! 

Gland Pharma Share Price Performance 

As of August 11, 2026, at 11:07 AM, Gland Pharma share price on NSE was trading at ₹2,862.00, up by 7.30% from the previous closing price. 

Conclusion 

For the quarter ended June 30, 2026, Gland Pharma recorded total income of ₹1,861.50 crore and net profit of ₹316.96 crore. Annual figures for financial year 2026 include total income of ₹6,746.98 crore and net profit of ₹1,027.32 crore. 

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.